Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (79 page)

BOOK: Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine
12.76Mb size Format: txt, pdf, ePub

Prognosis

• PSA level, Gleason grade and age are predictors of metastatic disease • In surgically treated Pts, 5-y relapse-free survival >90% if disease confined to organ,
75% if extension through capsule, and
40% if seminal vesicle invasion • PSA doubling time, Gleason, & time to biochemical recurrence predict mortality following recurrence. For local recurrence following RP, salvage RT may be beneficial if low PSA.
• Metastatic disease: median survival ~24–30 mo; all become castrate resistant (in 15–20% discontinuation of antiandrogens results in paradoxical ↓ in PSA) • Long-term consequences of antiandrogen therapy include osteoporosis
Prevention
• Finasteride and dutasteride ↓ total prostate cancers detected by bx, but ↑ number of high Gleason grade tumors (
NEJM
2003;349:215 & 2010;362:1192)
COLORECTAL CANCER (CRC)

Epidemiology and risk factors
(
Lancet
2010;375:1030;
CA Cancer J Clin
2011;61:212)
• 4th most common cancer in U.S. men & women; 2nd leading cause of all cancer death • Rare before age 40, w/ 90% of cases occurring after age 50. ~75% are sporadic.


Family history
: up to 25% of Pts have
FHx. Risk depends on # of 1st-degree relatives (w/ CRC
or
polyp) and their age at dx; ~5% have an identifiable germline mutation
Familial adenomatous polyposis (FAP)
: mutation in
APC
gene → 1000s of polyps at young age → ~100% lifetime risk; ↑ risk of thyroid, stomach, small bowel cancers
Hereditary nonpolyposis colorectal cancer (HNPCC)
: most common hereditary CRC (~3% of all CRC;
NEJM
2003;348:919); mutations in DNA mismatch repair genes (eg,
MSH2
,
MLH1
) →
microsatellite instability (MSI)
→ ↑ tumor progression → ~80% lifetime risk; predom.
right-sided
tumors; ↑ risk of
endometrial
, ovarian, stomach, urothelial, small bowel and pancreatic cancers.
Amsterdam criteria: ≥3 family members w/ HNPCC-related cancer, one of which is dx before age 50, affecting 2 successive generations.

Inflammatory bowel disease
: ↑ risk with ↑ extent and duration of disease • Other factors a/w ↑ risk of CRC: diet rich in animal fat, ? smoking, ? diabetes/obesity •
COX-2
: ↓ risk of adenomas w/ ASA & NSAIDs. ASA assoc. w/ ↓ CRC incidence, mets and mortality (
Lancet
: 2010;376:1741; 2012;379:1591 & 1602). ↓ COX-2-expressing CRC after prolonged ASA (
NEJM
2007;356:2131). ASA effect limited to
PIK3CA
-mut CRC (
NEJM
2012;367:1596). COX-2 inhib. effective but ↑ bleeding & CV events (
NEJM
2006;355:873 & 885).

Pathology and genetics
(
NEJM
2009;361:2449;
Nature
2012;487:330)

Adenoma

carcinoma sequence
reflects accumulation of multiple genetic mutations. ↑ risk of malig. w/ large (>2.5 cm), villous, sessile adenomatous polyps. Adenomas typically observed ~10 y prior to onset of cancer (both sporadic & familial).

• Genetic profile in sporadic CRC:
APC
(~80%),
KRAS
(~40%),
TP53
(50–70%),
DCC
or
SMAD4
, or
BRAF
(~15%); chrom instability (majority) or mismatch repair defic (10–15%) • Upfront genotyping may guide Rx; eg, benefit of anti-EGFR Ab cetuximab greater in
KRAS
wild-type than KRAS mutant (
NEJM
2008;359:1757).
BRAF
mutation may guide clinical trials.

Clinical manifestations

• Distal colon: Δ
bowel habits
,
obstruction
, colicky abdominal pain,
hematochezia
• Proximal colon:
iron defic. anemia
, dull vague abd pain; obstruction atypical due to larger lumen, liquid stool and polypoid tumors (
vs
. annular distal tumors) • Metastases: nodes,
liver
, lung, peritoneum → RUQ tenderness, ascites, supraclavicular LN
• Associated with
Streptococcus bovis
bacteremia and
Clostridium septicum
sepsis
Screening
(
NEJM
2009;361:1179)

Average risk
: colonoscopy starting at age 50 & repeat q10y strongly preferred method • ↑
risk
: earlier and/or more frequent screening.
FHx: age 40 or 10 y before index dx, then q5y. IBD: 8–10 y after dx, then q1–2y. Known or suspected familial syndrome: genetic counseling & very early screening (eg, age 20–25 y), then q1–2y.

Imaging
Colonoscopy
: test of choice as examines entire colon; 90% Se for lesions >1 cm. Flex sig less Se vs. colo and CTC (
Gut
2009;58:241). If polyp found, re ✓ in 3–5 y. Removal of adenomatous polyps associated with lower CRC mortality (
NEJM
2012;366:687).
Sigmoidoscopy
: 21% ↓ incidence in CRC & 26% ↓ mortality in distal CRC (
NEJM
2012;366:2345). Benefit may also be seen w/ 1-time flex-sig (
Lancet
2010;375:9726).
CT colonography (CTC)
: c/w colonoscopy, ~90% Se for lesions ≥1 cm but considerably less for smaller lesions (
NEJM
2008;359:1207). In high-risk Pts, Se only 85% for advanced neoplasia ≥6 mm (
JAMA
2009;301:2453). At population level, ↑ participation w/ CTC, but ↓ yield vs. colonoscopy; ∴ similar screening overall (
Lancet
2012;13:55).

Biochemical fecal testing
Occult blood
(FOBT): ↓ mortality (
NEJM
1993;328:1365 & 2000;343:1603); 3 card home testing more Se (24% vs. 5%) than DRE/FOBT (
Annals
2005;142:81). Repeat q1y.
Immunohisto for Hb
: Se ~35% & ~80% for adv neoplasia & CRC (
AJG
2012;107:1570)
DNA
: ↑ Se,
Sp c/w FOBT, but less Se than colonoscopy (
NEJM
2004;351:2704)

Staging
(
AJCC Cancer Staging Manual
, 7th ed, 2010)
• TNM staging: Size/depth of primary (T), locoregional nodes (N), distant metastases (M). Staging is complex and based on pathologic correlation with observed survival data.


Colonoscopy + biopsy/polypectomy + intraoperative
and
pathologic
staging essential for evaluating extracolonic spread • CT scans of chest and abdomen/pelvis (inaccurate for depth of invasion & malignant LN) • Baseline
CEA
in Pt
with known CRC
has prognostic significance and is useful to fol-low response to therapy and detect recurrence;
not
a screening tool
• Chemotherapy
FOLFOX (
5-FU + leucovorin + oxaliplatin
), FOLFIRI or CapeOx (
NEJM
2004;350:2343)
±
Bevacizumab (anti-VEGFA mAb,
NEJM
2004;350:2335) or cetuximab (anti-EGFR mAb,
NEJM
2004:351:337; benefit limited to Pts w/o
KRAS
mutation;
NEJM
2008;359:1757)
Regorafenib (multikinase inhib.) ↑ survival in Pts w/ progressive metastatic CRC (
Lancet
2013;381:303).
CHEMOTHERAPY SIDE EFFECTS

Other books

Feels Like Home by Lisa Ireland
Bad Man's Gulch by Max Brand
The Numbers Game by Frances Vidakovic
Lamb by Christopher Moore
HerMatesEmbrace by Rebecca Airies
A Sea of Purple Ink by Rebekah Shafer
Maurice by E. M. Forster
Indie Girl by Kavita Daswani
The Memory of Earth by Orson Scott Card